Nuvve (Nasdaq: NVVE) Continues Scaling Effort Into Japanese Stationary Battery Segment

V2G leader in partnership with Toyota Tsusho and Chubu Electric Power Miraiz now integrating stationary battery systems produced and deployed by Nissin Electric Company. SAN DIEGO, Dec. 12, 2023 /PRNewswire/ — Nuvve Holding Corp. (Nasdaq: NVVE), a global cleantech company electrifying the planet through its intelligent energy platform, along with Toyota Tsusho Corporation and Japan’s Chubu Electric Power Miraiz Company (Chubu) […]

James Nathanielsz, CEO of Propanc Biopharma, Inc., (QB – PPCB) is Featured in an Interview With SmallCapsDaily

Propanc CEO, James Nathanielsz Discusses the Company’s Groundbreaking Therapy, PRP, and its Potential to Revolutionize Cancer Treatment NEW YORK, NY – (NewMediaWire) – December 12, 2023 – Propanc Biopharma, Inc. (QB – PPCB), is pleased to announce its CEO, James Nathanielsz, recently conducted an interview with SmallCapsDaily discussing the Company’s recent developments, including the initiation […]

Skye Bioscience (OTCQB: SKYE) Responds to OTC Markets Promotional Policy

San Diego, California–(Newsfile Corp. – December 8, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on metabolic conditions and glaucoma, has received a request by OTC Markets Group Inc. (“OTC Markets”) to issue this statement about promotional activity concerning its common shares […]

Skye (OTCQB: SKYE) Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced […]

SciSparc (Nasdaq: SPRC) Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel

TEL AVIV, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today updates regarding the negotiation following the signing of a non-binding letter of intent (“LOI”) with […]

Applied UV (Nasdaq: AUVI) Announces 1-for-25 Reverse Stock Split

NEW YORK, NY, Dec. 08, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Applied UV, Inc. (“Applied UV” or the “Company”) (Nasdaq: AUVI), a leader in global food security, air quality, and specialty building solutions, today announced that it will effect a 1-for-25 reverse stock split (“Reverse Stock Split”) of its issued and outstanding common stock, par value […]

Energizing Enterprise? Correlate Energy’s (OTCQB:CIPI) Trailblazing Path In Renewable Energy

SHREVEPORT, LA / ACCESSWIRE / December 5, 2023 / A comprehensive research report by Harbinger Research, LLC, dated October 31, 2023, sheds light on Correlate Energy Corp. (OTCQB:CIPI), a company at the forefront of the clean distributed energy revolution. Specializing in solar power, energy storage, and electric vehicle (EV) charging solutions, the report underscores Correlate Energy’s potential in an industry […]

Inspire Veterinary Partners (NASDAQ:IVP) Announces Participation in NobleCon19 – Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference

VIRGINIA BEACH, VA / ACCESSWIRE / December 1, 2023 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today announced its participation in NobleCon19, Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference, to be held December 3-5, 2023, in Boca Raton, FL. Kimball […]

OKYO Pharma (NASDAQ: OKYO) Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Top-line Efficacy and Safety Data on Track for Release in December 2023 LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.